[
  {
    "ts": null,
    "headline": "Ironwood vs. Bausch Health: Which GI Drug Stock is a Better Pick Now?",
    "summary": "IRWD has the edge over BHC with high Linzess demand and upbeat 2026 revenue outlook offsetting pipeline and pricing risks.",
    "url": "https://finnhub.io/api/news?id=ebb4f7f9bd5d031426c9ab7c4325d5935684c9a0fff91de9f57f905db4e97460",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771603020,
      "headline": "Ironwood vs. Bausch Health: Which GI Drug Stock is a Better Pick Now?",
      "id": 139163196,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "IRWD has the edge over BHC with high Linzess demand and upbeat 2026 revenue outlook offsetting pipeline and pricing risks.",
      "url": "https://finnhub.io/api/news?id=ebb4f7f9bd5d031426c9ab7c4325d5935684c9a0fff91de9f57f905db4e97460"
    }
  },
  {
    "ts": null,
    "headline": "Barclays Initiates Coverage of AbbVie (ABBV) with Overweight Recommendation",
    "summary": "Barclays Initiates Coverage of AbbVie (ABBV) with Overweight Recommendation",
    "url": "https://finnhub.io/api/news?id=ef903b6476a44f94659eef4233f5195064f7e92cabcc5f3fa3df28ebc04241e2",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771599852,
      "headline": "Barclays Initiates Coverage of AbbVie (ABBV) with Overweight Recommendation",
      "id": 139161114,
      "image": "",
      "related": "ABBV",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=ef903b6476a44f94659eef4233f5195064f7e92cabcc5f3fa3df28ebc04241e2"
    }
  },
  {
    "ts": null,
    "headline": "Will Immunology Drugs Continue to Drive AbbVie's Top Line in 2026?",
    "summary": "ABBV's Skyrizi and Rinvoq drove more than 40% growth in 2025. Can these immunology blockbusters power double-digit gains again in 2026?",
    "url": "https://finnhub.io/api/news?id=55bb5c683f136bfd7c7ffb84a2e303dee23e00d45768a77fa4d36b2803efe29e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771593360,
      "headline": "Will Immunology Drugs Continue to Drive AbbVie's Top Line in 2026?",
      "id": 139161260,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "ABBV's Skyrizi and Rinvoq drove more than 40% growth in 2025. Can these immunology blockbusters power double-digit gains again in 2026?",
      "url": "https://finnhub.io/api/news?id=55bb5c683f136bfd7c7ffb84a2e303dee23e00d45768a77fa4d36b2803efe29e"
    }
  },
  {
    "ts": null,
    "headline": "Barclays launches U.S. biopharma coverage with four preferred picks",
    "summary": "Investing.com -- Barclays launched coverage of U.S. large-cap biopharmaceutical companies, arguing the sector could regain investor attention in an uncertain macro backdrop, while naming Eli Lilly (NYSE:LLY), Merck (NYSE:MRK), Bristol-Myers Squibb (NYSE:BMY) and AbbVie Inc (NYSE:ABBV) as its top picks.",
    "url": "https://finnhub.io/api/news?id=24defe4374fd77db8c0683e041cc1dc376df6732125794a437ba7de5060bb531",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771592903,
      "headline": "Barclays launches U.S. biopharma coverage with four preferred picks",
      "id": 139159098,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Investing.com -- Barclays launched coverage of U.S. large-cap biopharmaceutical companies, arguing the sector could regain investor attention in an uncertain macro backdrop, while naming Eli Lilly (NYSE:LLY), Merck (NYSE:MRK), Bristol-Myers Squibb (NYSE:BMY) and AbbVie Inc (NYSE:ABBV) as its top picks.",
      "url": "https://finnhub.io/api/news?id=24defe4374fd77db8c0683e041cc1dc376df6732125794a437ba7de5060bb531"
    }
  },
  {
    "ts": null,
    "headline": "Fill Finish Manufacturing Market Analysis Report 2026-2035: A $21+ Billion Market by 2030 with Johnson & Johnson, AbbVie, Thermo Fisher Scientific, BD & Co, Baxter, Lonza, and Catalent Leading",
    "summary": "Key market opportunities in the fill finish manufacturing sector include rising demand for cell and gene therapies, expansion in personalized medicine production, and increased outsourcing to CMOs. Growth is driven by innovations in aseptic filling technologies, automated systems, and a focus on regulatory compliance. Fill Finish Manufacturing Market Fill Finish Manufacturing Market Dublin, Feb. 20, 2026 (GLOBE NEWSWIRE) -- The \"Fill Finish Manufacturing Market Report 2026\" has been added to Res",
    "url": "https://finnhub.io/api/news?id=35a17e96edf3f11296f988ba8d14b89635690ac974315c9045f4aeb0ece47d12",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771582320,
      "headline": "Fill Finish Manufacturing Market Analysis Report 2026-2035: A $21+ Billion Market by 2030 with Johnson & Johnson, AbbVie, Thermo Fisher Scientific, BD & Co, Baxter, Lonza, and Catalent Leading",
      "id": 139158118,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Key market opportunities in the fill finish manufacturing sector include rising demand for cell and gene therapies, expansion in personalized medicine production, and increased outsourcing to CMOs. Growth is driven by innovations in aseptic filling technologies, automated systems, and a focus on regulatory compliance. Fill Finish Manufacturing Market Fill Finish Manufacturing Market Dublin, Feb. 20, 2026 (GLOBE NEWSWIRE) -- The \"Fill Finish Manufacturing Market Report 2026\" has been added to Res",
      "url": "https://finnhub.io/api/news?id=35a17e96edf3f11296f988ba8d14b89635690ac974315c9045f4aeb0ece47d12"
    }
  },
  {
    "ts": null,
    "headline": "FDA Approval For AbbVie/AstraZeneca's Combination Treatment Could Set New Standard For Slow Growing Blood Cancer",
    "summary": "FDA approves AbbVie&#39;s all-oral leukemia treatment combo, showing better three-year outcomes and offering patients a chance for time off therapy compared to standard chemo.",
    "url": "https://finnhub.io/api/news?id=4588513d5807ea2ee3812fef44e1941d58657323de0f49b306ebdbb05b185140",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771578152,
      "headline": "FDA Approval For AbbVie/AstraZeneca's Combination Treatment Could Set New Standard For Slow Growing Blood Cancer",
      "id": 139158772,
      "image": "https://cdn.benzinga.com/files/images/story/2026/02/20/Cancer---Heart-Shape-To-Represent-Medica.jpeg?width=2048&height=1536",
      "related": "ABBV",
      "source": "Benzinga",
      "summary": "FDA approves AbbVie&#39;s all-oral leukemia treatment combo, showing better three-year outcomes and offering patients a chance for time off therapy compared to standard chemo.",
      "url": "https://finnhub.io/api/news?id=4588513d5807ea2ee3812fef44e1941d58657323de0f49b306ebdbb05b185140"
    }
  },
  {
    "ts": null,
    "headline": "Corcept Therapeutics: The Bad News Is Priced In; The Ovarian Cancer Upside Is Not",
    "summary": "Corcept Therapeutics: The Bad News Is Priced In; The Ovarian Cancer Upside Is Not",
    "url": "https://finnhub.io/api/news?id=feb739ae4ca15148e188d9359e4597bf7fc704041ddae52634b7f7d36385ed9d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771572647,
      "headline": "Corcept Therapeutics: The Bad News Is Priced In; The Ovarian Cancer Upside Is Not",
      "id": 139158414,
      "image": "",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=feb739ae4ca15148e188d9359e4597bf7fc704041ddae52634b7f7d36385ed9d"
    }
  },
  {
    "ts": null,
    "headline": "U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)",
    "summary": "AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for the combination regimen of VENCLEXTA® (venetoclax) and acalabrutinib for the treatment of previously untreated adult patients with chronic lymphocytic leukemia (CLL). The approval is supported by data from the Phase 3 AMPLIFY trial.1",
    "url": "https://finnhub.io/api/news?id=d34cb1f2b2969bfdcd991f71b503b064bab80d1bab57c13ba0ba97d11e22bc0e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771570800,
      "headline": "U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)",
      "id": 139156315,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for the combination regimen of VENCLEXTA® (venetoclax) and acalabrutinib for the treatment of previously untreated adult patients with chronic lymphocytic leukemia (CLL). The approval is supported by data from the Phase 3 AMPLIFY trial.1",
      "url": "https://finnhub.io/api/news?id=d34cb1f2b2969bfdcd991f71b503b064bab80d1bab57c13ba0ba97d11e22bc0e"
    }
  },
  {
    "ts": null,
    "headline": "Who's laughing now? China’s humanoid robots go from viral stumbles to kung fu flips in one year",
    "summary": "Chinese humanoid robots are having a moment in the spotlight after a standout performance at the country's annual Spring Festival Gala.",
    "url": "https://finnhub.io/api/news?id=8c7f74fe78aea5e2bba97b1af3bd9eccde13540e6960c568f59dda96373e808a",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771558020,
      "headline": "Who's laughing now? China’s humanoid robots go from viral stumbles to kung fu flips in one year",
      "id": 139161811,
      "image": "https://image.cnbcfm.com/api/v1/image/108267707-1771566525692-gettyimages-2261125564-AA_14022026_2652018.jpeg?v=1771566615&w=1920&h=1080",
      "related": "ABBV",
      "source": "CNBC",
      "summary": "Chinese humanoid robots are having a moment in the spotlight after a standout performance at the country's annual Spring Festival Gala. ",
      "url": "https://finnhub.io/api/news?id=8c7f74fe78aea5e2bba97b1af3bd9eccde13540e6960c568f59dda96373e808a"
    }
  },
  {
    "ts": null,
    "headline": "Roche's Genentech Wins FDA Approval For Venclexta Plus Acalabrutinib As First And Only All-Oral, Fixed-Duration Regimen For Previously Untreated Chronic Lymphocytic Leukemia Patients",
    "summary": "– First and only all-oral, fixed-duration regimen designed to provide CLL patients with the potential to experience time off treatment –– Approval expands Genentech&#39;s fixed-duration portfolio by providing eligible– First and only all-oral, fixed-duration regimen designed to provide CLL patients with the potential to experience time off treatment –",
    "url": "https://finnhub.io/api/news?id=5800b7fc7c3728ec6e1c33e4136d7ca0ac87ca02d0009b943a650497ed415b56",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771557637,
      "headline": "Roche's Genentech Wins FDA Approval For Venclexta Plus Acalabrutinib As First And Only All-Oral, Fixed-Duration Regimen For Previously Untreated Chronic Lymphocytic Leukemia Patients",
      "id": 139158773,
      "image": "",
      "related": "ABBV",
      "source": "Benzinga",
      "summary": "– First and only all-oral, fixed-duration regimen designed to provide CLL patients with the potential to experience time off treatment –– Approval expands Genentech&#39;s fixed-duration portfolio by providing eligible– First and only all-oral, fixed-duration regimen designed to provide CLL patients with the potential to experience time off treatment –",
      "url": "https://finnhub.io/api/news?id=5800b7fc7c3728ec6e1c33e4136d7ca0ac87ca02d0009b943a650497ed415b56"
    }
  }
]